Finding Description
2. The record for Resident J was reviewed on 9/27/23 at 4:19 p.m. Diagnoses included, but were not limited to, Alzheimer's disease, anxiety disorder, cognitive communication deficit, insomnia, anxiety, dementia in other diseases, and psychosis related to dementia and depression.
A physician's order, dated 8/23/23, indicated Risperdal (a medication for schizophrenia) 0.5 mg daily for psychosis with dementia.
An IDT (interdisciplinary team) note, dated 3/1/23 at 5:55p.m., indicated a new order for Risperdal 0.25 mg (milligrams) was given by the psychiatric nurse practitioner. The resident's husband and hospice were made aware of the new order. The resident would be observed routinely for signs and symptoms of side effects to the medication. AIMs (Abnormal Involuntary Movement scale) assessment completed and would be completed routinely while taking antipsychotic medication.
An IDT note, dated 3/29/23 at 2:44 p.m., indicated a new order was given by the psychiatric nurse practitioner to increase the dosage of Risperdal to 0.5 mg at bedtime. Hospice and the resident's husband made aware of the new order.
The IDT notes did not include documentation on education provided to the husband regarding the antipsychotic medications, risks/benefits, or medication side effects.
A care plan, dated 2/11/22, indicated a potential for drug related complications associated with the use of psychotropic medications related to anti-anxiety, anti-depressant, and anti-psychotic medications. Interventions included, but were not limited to, observe for side effects of antipsychotic medication, and report them to the physician: sedation (sleepiness), drowsiness, dry mouth, constipation, blurred vision, extra pyramidal symptoms (muscle dysfunction), weight gain, edema (swelling), postural hypotension (low blood pressure), sweating, loss of appetite, and urinary retention.
During an interview, on 10/3/23 at 11:00 a.m., the DNS indicated she did not have documentation of education for the husband regarding the use of the Risperdal, side effects, or the risks and benefits of the medication.
A current publication, titled Mobile PDR (physician's desk reference), indicated .Abilify [aripiprazole] is an antipsychotic .used in adults for schizophrenia, bipolar 1 disorder and as an adjunct for major depression . antipsychotics are not a recommended treatment of dementia-related psychosis in geriatric adults and the use of Abilify should be avoided if possible due to an increase in morbidity and mortality in elderly adults with dementia receiving antipsychotics .deaths have typically resulted from heart failure, sudden death or infections (primarily pneumonia) .an increased incidence of cerebrovascular adverse events, including fatal events, has been reported
A current publication, titled Mobile PDR (physician's desk reference), indicated .Risperdal (risperidone) is an antipsychotic .used for schizophrenia and bipolar disorder in adults .antipsychotics are not a recommended treatment of dementia-related psychosis in geriatric adults and the use of risperidone should be avoided if possible due to an increase in morbidity and mortality in elderly adults with dementia receiving antipsychotics .deaths have typically resulted from heart failure, sudden death or infections (primarily pneumonia) .an increased incidence of cerebrovascular adverse events, including fatal events, has been reported
A current policy, titled Use of Psychotropic Medication, not dated and received from the DNS on 10/3/23 at 1:00 p.m., indicated .the indications for initiating, withdrawing or withholding medications as well as the use of non-pharmacological approaches will be determined by: assessing the residents underlying condition, current signs, symptoms expressions, and preferences and goals for treatment .identification of underlying causes (when possible) .the attending physician will assume leadership in medication management by developing, monitoring, and modifying medication regimen in collaboration with residents, their families and/or representatives, other professionals, and the interdisciplinary team .the indications for use of any psychotropic drug will be documented in the medical record .residents who use psychotropic drugs shall receive a gradual dose reduction, unless clinically contraindicated, in an effort to discontinue these drugs .the effects of psychotropic medications on a resident's physical, mental and psychosocial well-being will be evaluated on an ongoing basis, such as: upon physician evaluation (routine and as needed), during the pharmacist's monthly medication regimen review, during MDS (minimum data set) review (quarterly, annually, significant change), and in accordance with nurse assessments and medication monitoring parameters consistent with clinical standards of practice, manufacturers specifications, and the resident's comprehensive plan of care .the residents response to the medication(s), including progress towards goals and presence/ absence of adverse consequences, shall be documented in the resident's medical record .the facility shall identify the medication for use, as possible, using pre-admission screening and other pre-admission data .the physician in collaboration with the consultant pharmacist shall re-evaluate the use of the medication and consider whether or not the medication can be reduced or discontinued upon admission or soon after admission
3.1-48(a)(6)
3.1-48(b)(2)
Based on observation, interview and record review, the facility failed to ensure residents and resident's representatives were informed of the risks of antipsychotic medications and a gradual dose reduction was considered for 2 of 5 residents reviewed for unnecessary medications. (Resident 73 and J)
Findings include:
1. During an observation, on 9/27/23 at 12:00 p.m., Resident 73 was in her room with staff assisting her to eat lunch and the resident was making some grunting sounds.
During an observation, on 9/28/23 at 3:07 p.m., the resident responded yes to the knock on her door.
During an observation, on 9/29/23 at 3:25 p.m., the resident was in the shower room with staff and making repetitive sounds.
The record for Resident 73 was reviewed on 9/28/23 at 1:23 p.m. Diagnoses included, but were not limited to, traumatic subdural (between the skull and the brain) hemorrhage, dementia with other behavioral disturbance, aphasia (difficulty speaking), senile degeneration of the brain, anxiety disorder, major depressive disorder, and repeated falls.
a. A care plan, dated 12/19/22, indicated the resident was at a risk for adverse effects related to psychotropic drug use. The interventions included, but were not limited to, observe for side effects and report to the physician, a pharmacist review of the medications as needed, provide medication as ordered by the physician, and evaluate for effectiveness and to refer to mental health services for medication and behavior intervention recommendations.
A care plan, dated 4/11/23, indicated the resident occasionally had disruptive behaviors during activities such as yelling out which was related to the diagnosis of dementia. The interventions included, but were not limited to, the resident didn't like to sit still for long so please bring to activities just before the program begins, provide shorter duration activities, call the resident's name or gently touch her arm to help maintain awareness of the activity, offer soothing activities and understand if the resident wants to stay in her room.
A physician's order, dated 12/9/22, indicated to give aripiprazole (an antipsychotic medication) 2 milligram (mg) one time a day related to severe dementia with behavioral disturbance.
A care plan meeting minutes, dated 12/9/22, indicated the team members in attendance included nursing and the resident's family member. The areas discussed included, discharge plans, advanced directives, acute medical conditions, chronic medical conditions, skin/wound conditions, nutrition/hydration, cognition, bowel/bladder, rehabilitation services, physical function, and behavior health activities.
The care plan meeting minutes did not include anything about medications, medications side effects, or medication risks and benefits.
During an interview, on 10/2/23 at 2:13 p.m., the Director of Nursing Services (DNS) indicated the facility talked about the resident's medications during the care plan meeting although they did not have any specifics about what was discussed listed in the care plan meeting minutes. The facility did not have any documentation of a review of the medication risks and benefits.
b. A Treatment Administration Record (TAR), for the month of March 2023, with behavior monitoring for psychosis/delusions, agitation and repetitive calling out, indicated the resident had none of those behaviors for the month.
A TAR, for the month of April 2023, with behavior monitoring for psychosis/delusions, agitation and repetitive calling out, indicated the resident had one behavior on April 7 for the day shift. The resident remained the same after the interventions of fluids, food, redirection, and one to one.
The TAR did not indicate which one of the listed behaviors occurred.
A pharmacy physician recommendation, dated 4/3/23, indicated the resident had a current order for aripiprazole 2 mg daily for dementia with behaviors since 12/22. Please consider discontinuing.
The physician/prescriber response, dated 4/14/23, indicated the gradual dose reduction (GDR) was contraindicated due to the resident continued to exhibit behaviors and the behaviors were expected to worsen with a change of medication.
The physician/prescribed response did not include the type of behaviors exhibited by the resident.
A progress note, dated 6/2/23 at 12:23 p.m., indicated the resident was being assisted with lunch. The resident often had behaviors of yelling out related to the diagnosis of dementia and difficulty making herself understood. The resident's behavior was not distressing to herself or to others. The resident was generally easily redirected. The resident's care plan reflected she would yell at at times.
During an interview, on 10/3/23 at 10:05 a.m., CNA 3 indicated the resident would repeat words, really didn't have any behaviors, and did not try to hurt herself or anyone else. Sometimes she would try to get out of bed by herself.
During an interview, on 10/3/23 at 11:29 a.m., the DNS indicated the resident's behaviors included some calling out and some refusals of care. The resident's daughter in law had indicated the resident was rude and blunt. The DNS was not able to report any psychosis, delusions, or distressing resident behaviors.